MDXH vs. FLGT, ZEPP, LAB, TALK, BFLY, TBRG, OM, SOPH, HCAT, and NYXH
Should you be buying MDxHealth stock or one of its competitors? The main competitors of MDxHealth include Fulgent Genetics (FLGT), Zepp Health (ZEPP), Standard BioTools (LAB), Talkspace (TALK), Butterfly Network (BFLY), TruBridge (TBRG), Outset Medical (OM), SOPHiA GENETICS (SOPH), Health Catalyst (HCAT), and Nyxoah (NYXH). These companies are all part of the "medical info sys" industry.
MDxHealth vs. Its Competitors
MDxHealth (NASDAQ:MDXH) and Fulgent Genetics (NASDAQ:FLGT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.
MDxHealth has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Fulgent Genetics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.
MDxHealth has higher earnings, but lower revenue than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
MDxHealth currently has a consensus target price of $7.00, suggesting a potential upside of 102.31%. Fulgent Genetics has a consensus target price of $25.33, suggesting a potential upside of 14.99%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts plainly believe MDxHealth is more favorable than Fulgent Genetics.
In the previous week, Fulgent Genetics had 5 more articles in the media than MDxHealth. MarketBeat recorded 7 mentions for Fulgent Genetics and 2 mentions for MDxHealth. MDxHealth's average media sentiment score of 1.82 beat Fulgent Genetics' score of 0.20 indicating that MDxHealth is being referred to more favorably in the media.
48.1% of Fulgent Genetics shares are held by institutional investors. 1.7% of MDxHealth shares are held by company insiders. Comparatively, 31.8% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Fulgent Genetics has a net margin of -16.83% compared to MDxHealth's net margin of -34.98%. Fulgent Genetics' return on equity of -2.26% beat MDxHealth's return on equity.
Summary
MDxHealth and Fulgent Genetics tied by winning 8 of the 16 factors compared between the two stocks.
Get MDxHealth News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MDxHealth Competitors List
Related Companies and Tools
This page (NASDAQ:MDXH) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access